This company listing is no longer active
PLX Stock Overview
A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Protalix BioTherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.33 |
| 52 Week High | US$7.80 |
| 52 Week Low | US$3.15 |
| Beta | 1.47 |
| 11 Month Change | 28.98% |
| 3 Month Change | 75.79% |
| 1 Year Change | 97.55% |
| 33 Year Change | -16.86% |
| 5 Year Change | -59.71% |
| Change since IPO | -97.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| PLX | IL Biotechs | IL Market | |
|---|---|---|---|
| 7D | -0.1% | -4.2% | 1.0% |
| 1Y | 97.5% | -10.1% | 23.7% |
Return vs Industry: PLX exceeded the IL Biotechs industry which returned -49.3% over the past year.
Return vs Market: PLX exceeded the IL Market which returned -25.9% over the past year.
Price Volatility
| PLX volatility | |
|---|---|
| PLX Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in IL Market | 7.3% |
| 10% least volatile stocks in IL Market | 2.9% |
Stable Share Price: PLX's share price has been volatile over the past 3 months.
Volatility Over Time: PLX's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of IL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 195 | Dror Bashan | www.protalix.com |
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases.
Protalix BioTherapeutics, Inc. Fundamentals Summary
| PLX fundamental statistics | |
|---|---|
| Market cap | ₪407.53m |
| Earnings (TTM) | -₪54.09m |
| Revenue (TTM) | ₪172.62m |
2.4x
P/S Ratio-7.5x
P/E RatioIs PLX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PLX income statement (TTM) | |
|---|---|
| Revenue | US$47.64m |
| Cost of Revenue | US$19.59m |
| Gross Profit | US$28.05m |
| Other Expenses | US$42.97m |
| Earnings | -US$14.93m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.26 |
| Gross Margin | 58.87% |
| Net Profit Margin | -31.33% |
| Debt/Equity Ratio | -264.9% |
How did PLX perform over the long term?
See historical performance and comparison